1. Signaling Pathways
  2. GPCR/G Protein
  3. Amylin Receptor

Amylin Receptor

AMYR

Amylin receptors (AMYRs) are G protein-coupled receptors (GPCRs), which respond to the peptide hormones amylin and calcitonin. Amylin was originally discovered as the main constituent of pancreatic islet amyloid deposits in type 2 diabetics and in diabetic cats, amylin is also a physiologically relevant circulating peptide hormone. Amylin receptors are heterodimers comprising the calcitonin receptor, which is a G protein–coupled receptor, and one of three receptor-modifying proteins. An impediment to functional studies is that it is difficult to separate amylin receptor phenotypes from calcitonin receptor phenotypes. Amylin receptors are targets for treating obesity and metabolic disorders.

Amylin Receptor Related Products (54):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10956
    Colulintide
    Agonist 98.35%
    Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity.
    Colulintide
  • HY-P4928
    Biotinyl-Amylin (mouse, rat)
    Antagonist 99.89%
    Biotinyl-Amylin (mouse, rat) is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
    Biotinyl-Amylin (mouse, rat)
  • HY-P11320
    Davalintide
    Agonist 98.04%
    Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes.
    Davalintide
  • HY-P4785
    Acetyl-Amylin (8-37) (human)
    Antagonist
    Acetyl-Amylin (8-37) (human) is a specific amylin antagonist.
    Acetyl-Amylin (8-37) (human)
  • HY-P4928A
    Biotinyl-Amylin (mouse, rat) TFA
    Antagonist
    Biotinyl-Amylin (mouse, rat) TFA is a biotinylated Amylin (mouse, rat). Amylin (mouse, rat) is a 37-aminoacid pancreatic protein that exerts control over several metabolic events such as glycemia and lacticemia.
    Biotinyl-Amylin (mouse, rat) TFA
  • HY-P4767
    Amylin (1-13) (human)
    Ligand 98.23%
    Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself.
    Amylin (1-13) (human)
  • HY-P1871A
    Amylin (IAPP), feline TFA
    98.75%
    Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion.
    Amylin (IAPP), feline TFA
  • HY-P11274
    Zenagamtide
    Agonist
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.
    Zenagamtide
  • HY-185229B
    rel-CTR/AMYR agonist-1
    Agonist
    rel-CTR/AMYR agonist-1 (Example 169) is an agonist of amylin and/or calcitonin receptor.
    rel-CTR/AMYR agonist-1
  • HY-P2501
    Amylin (8-37), human
    Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.
    Amylin (8-37), human
  • HY-P3926
    Amylin (8-37) (human)
    Amylin (8-37) (human) (hIAPP (8-37)) is a 8-37 fragment of human islet amyloid polypeptide (IAPP). The duplex folding structure in the Amylin (8-37) (human) assembly has a hairpin structure.
    Amylin (8-37) (human)
  • HY-P11586
    San45
    Agonist
    San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity.
    San45
  • HY-P11269
    Lenbelintide
    Agonist
    Lenbelintide is a dual amylin/calcitonin receptor agonist. Lenbelintide can be studied in research on obesity.
    Lenbelintide
  • HY-114613
    D-Trp-Aib
    D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a Kd of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease.
    D-Trp-Aib
  • HY-P11843
    TPM004
    Agonist
    TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC50 values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes.
    TPM004
  • HY-P11665
    Batelintide
    Agonist
    Batelintide is a dual amylin/calcitonin receptor agonist with antidiabetic effects.
    Batelintide
  • HY-P11584
    KBP-066A
    Agonist
    KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity.
    KBP-066A
  • HY-185234A
    (R)-CTR/AMYR activator-1
    Activator
    (R)-CTR/AMYR activator-1 (Compound 122) is a CTR/AMYR activator with EC50 values of 0.8 and 0.73 nM. (R)-CTR/AMYR activator-1 can used for the researches of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases.
    (R)-CTR/AMYR activator-1
  • HY-P11830
    UDA-6
    Agonist
    UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity.
    UDA-6
  • HY-P4873
    Amylin (20-29) (human)
    Amylin (20-29) (human) is the fragment of human islet amyloid polypeptide (hIAPP) or Amylin. Amylin is a 37-residue hormone. Amylin (20-29) (human) is responsible for the amyloidogenic propensities of the full length protein. Amylin (20-29) (human) can be transformed into its corresponding peptoid and retropeptoid sequences, to obtain beta-sheet breaker peptides as amyloid inhibitors.
    Amylin (20-29) (human)